慢性阻塞性肺病
医学
背景(考古学)
药物治疗
肺动脉高压
内科学
心脏病学
重症监护医学
生物
古生物学
作者
Khodr Tello,Athiththan Yogeswaran,Raphael W. Majeed,David G. Kiely,Allan Lawrie,Evan L. Brittain,Jeffrey Annis,Horst Olschewski,Gábor Kovács,Paul M. Hassoun,Aparna Balasubramanian,Ziad Konswa,Andrew J. Sweatt,Roham T. Zamanian,Martin R. Wilkins,Luke Howard,Alexandra Arvanitaki,George Giannakoulas,Héctor Cajigas,Robert P. Frantz
出处
期刊:Chest
[Elsevier]
日期:2024-09-07
卷期号:167 (1): 224-240
被引量:10
标识
DOI:10.1016/j.chest.2024.08.016
摘要
Patients with COPD frequently develop pulmonary hypertension (PH-COPD). Severe PH-COPD, identified by a pulmonary vascular resistance (PVR) >5 Wood Units (WU), is closely linked to impaired transplant-free survival. The impact of PH-targeting pharmacotherapy in this context remains unclear.
科研通智能强力驱动
Strongly Powered by AbleSci AI